Lack of Prognostic Significance of C-erbB-2 Expression in Low- and High- grade Astrocytomas

Muallaoglu, Sadik; Besen, Ali Ayberk; Ata, Alper; Mertsoylu, Huseyin; Arican, Ali; Kayaselcuk, Fazilet; Ozyilkan, Ozgur

추천

검색

자료유형: 학술저널

저자정보: Muallaoglu, Sadik (Department of Medical Oncology, Faculty of Medicine, University of Baskent) Besen, Ali Ayberk (Department of Medical Oncology, Van Training and Research Hospital) Ata, Alper (Department of Medical Oncology, Mersin State Hospital) Mertsoylu, Huseyin (Department of Medical Oncology, Faculty of Medicine, University of Baskent) Arican, Ali (Department of Medical Oncology, Faculty of Medicine, University of Mersin) Kayaselcuk, Fazilet (Department of Pathology, Faculty of Medicine, University of Baskent) Ozyilkan, Ozgur (Department of Medical Oncology, Faculty of Medicine, University of Baskent)

저널정보: 아시아태평양암예방학회 Asian Pacific journal of cancer prevention : APJCP Asian Pacific journal of cancer prevention : APJCP 제15권 제3호

발행연도: 2014.1

수록면: 1,333 - 1,337 (5page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Background: Astrocytic tumors, the most common primary glial tumors of the central nervous system, are classified from low to high grade according to the degree of anaplasia and presence of necrosis. Despite advances in therapeutic management of high grade astrocytic tumors, prognosis remains poor. In the present study, the frequency and prognostic significance of c-erb-B2 in astrocytic tumors was investigated. Materials and Methods: Records of 72 patients with low- and high-grade astrocytic tumors were evaluated. The expression of C-erbB-2 was determined immunohistochemically and intensity was recorded as 0 to 3+. Tumors with weak staining (1+) or no staining (0) were considered Her-2 negative, while tumors with moderate (2+) and strong (3+) staining were considered Her-2 positive. Results: Of the 72 patients, 41 (56.9%) had glioblastoma (GBM), 10 (13.9%) had diffuse astrocytoma, 15 (20.8%) had anaplastic astrocytoma, 6 (8.3%) had pilocytic astrocytoma. C-erbB-2 overexpression was detected in the tumor specimens of 17 patients (23.6%). Six (8.3%) tumors, all GBMs, exhibited strong staining, 2 (2.7%) specimens, both GBMs, exhibited moderate staining, and 9 specimens, 5 of them GBMs (12.5%), exhibited weak staining. No staining was observed in diffuse astrocytoma and pilocytic astrocytoma specimens. Median overall survival of patients with C-erbB-2 negative and C-erbB-2 positive tumors were 30 months (95%CI: 22.5-37.4 months) and 16.9 months (95%CI: 4.3-29.5 months), respectively (p=0.244). Conclusions: Although there was no difference in survival, C-erbB-2 overexpression was observed only in the GBM subtype.

#Glioblastoma #C-erbB-2 #prognostic factor #astrocytic tumor

참고문헌 (0)

참고문헌 신청

참고문헌이 DBpia에서 서비스 중이라면, [참고문헌 신청]을 통해 등록해보세요